DDX17 and metabolic dysfunction-associated steatohepatitis: The results indicate that DDX17 contributes to the progression of NASH by stimulating the lipid accumulation in hepatocytes and inducing the activation of M1 macrophages as well as promoting a subsequent inflammatory response and fibrosis through the transcriptional repression of Cyp2c29 in mice.